Botulinum toxin treatment for bladder dysfunction

International Journal of Urology

Volumn 20, Issue 10, 2013, Pages 956-962

  Santos Silva, André ^a   da Silva, Carlos Martins ^a   Cruz, Francisco ^a  

^a HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

Botulinum toxin; Neurogenic detrusor overactivity; Onabotulinum toxin A; Overactive bladder; Urinary incontinence

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

BLADDER CAPACITY; BLADDER DYSFUNCTION; CHRONIC BLADDER PAIN; CHRONIC DISEASE; CYSTALGIA; DETRUSOR MUSCLE; HUMAN; MULTIPLE SCLEROSIS; OVERACTIVE BLADDER; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; STRESS INCONTINENCE; URINARY TRACT INFECTION; URINE INCONTINENCE; URINE RETENTION;

BOTULINUM TOXIN; NEUROGENIC DETRUSOR OVERACTIVITY; ONABOTULINUM TOXIN A; OVERACTIVE BLADDER; URINARY INCONTINENCE;

BOTULINUM TOXINS, TYPE A; HUMANS; MUSCARINIC ANTAGONISTS; NEUROMUSCULAR AGENTS; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 84884983332     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12188     Document Type: Review

References (26)

1. Cruz F, Herschorn S, Aliotta P etal. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomized, double-blind, placebo-controlled trial. Eur. Urol. 2011; 60: 742-750.
2. Ginsberg D, Gousse A, Keppenne V etal. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J. Urol. 2012; 187: 2131-2139.
3. Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J. Urol. 2000; 164: 692-697.
4. Schurch B, de Sèze M, Denys P etal.; Botox Detrusor Hyperreflexia Study Team. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J. Urol. 2005; 174: 196-200.
5. Mangera A, Andersson KE, Apostolidis A etal. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA). Eur. Urol. 2011; 60: 784-795.
6. Mehnert U, Birzele J, Reuter K, Schurch B. The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study. J. Urol. 2010; 184: 1011-1016.
7. Dmochowski R, Chapple C, Nitti VW etal. Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J. Urol. 2010; 184: 2416-2422.
8. Brubaker L, Richter HE, Visco A etal. Refractory idiopathic urge urinary incontinence and botulinum A injection. J. Urol. 2008; 180: 217-222.
9. Flynn MK, Amundsen CL, Perevich M, Liu F, Webster GD. Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder. J. Urol. 2009; 181: 2608-2615.
10. Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J. Urol. 2007; 177: 2231-2236.
11. Tincello DG, Slack MC, Kenyon S etal. Botulinum toxin-A fversus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women. Eur. Urol. Suppl. 2012; 62: 507-514.
12. Denys P, Le Normand L, Ghout I etal. VESITOX study group in France. Efficacy and safety of low doses of onabotulinumtoxinA for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study. Eur. Urol. 2012; 61: 520-529.
13. Nitti VW, Dmochowski R, Herschorn S etal.; EMBARK Study Group. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3 randomized placebo-controlled trial. J. Urol. 2012; doi: 10.1016/j.juro.2012.12.022.
14. Visco AG, Brubaker L, Richter HE etal. for the Pelvic Floor Disorders Network. Anticholinergic therapy vs. onabotulinumtoxina for urgency urinary incontinence. N. Engl. J. Med. 2012; 367: 1803-1813.
15. Manecksha RP, Cullen IM, Ahmad S etal. Prospective randomised controlled trial comparing trigone-sparing versus trigone-including intradetrusor injection of abobotulinumtoxinA for refractory idiopathic detrusor overactivity. Eur. Urol. 2012; 61: 928-935.
16. Dowson C, Watkins J, Khan MS, Dasgupta P, Sahai A. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur. Urol. 2012; 61: 834-839.
17. Vemulakonda VM, Somogyi GT, Kiss S, Salas NA, Boone TB, Smith CP. Inhibitory effect of intravesically applied botulinum toxin A in chronic bladder inflammation. J. Urol. 2005; 173: 621-624.
18. Rapp DE, Turk KW, Bales GT, Cook SP. Botulinum toxin type a inhibits calcitonin gene-related peptide release from isolated rat bladder. J. Urol. 2006; 175: 1138-1142.
19. Smith CP, Chancellor MB. Emerging role of botulinum toxin in the management of voiding dysfunction. J. Urol. 2004; 171: 2128-2137.
20. Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. Eur.Urol. 2006; 49: 704-709.
21. Giannantoni A, Porena M, Costantini E, Zucchi A, Mearini L, Mearini E. Botulinum A toxin intravesical injection in patients with painful bladder syndrome: 1-year followup. J. Urol. 2008; 179: 1031-1034.
22. Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009; 104: 657-661.
23. Chung SD, Kuo YC, Kuo HC. Intravesical onabotulinumtoxinA injections for refractory painful bladder syndrome. Pain Physician 2012; 15: 197-202.
24. Kuo HC. Repeated onabotulinumtoxin-a injections provide better results than single injection in treatment of painful bladder syndrome. Pain Physician 2013; 16: E15-23.
25. Pinto R, Lopes T, Frias B etal. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur. Urol. 2010; 58: 360-365.
26. Pinto R, Lopes T, Silva J, Silva C, Dinis P, Cruz F. Persistent therapeutic effect of repeated injections of onabotulinum toxin a in refractory bladder pain syndrome/interstitial cystitis. J. Urol. 2013; 189: 548-553.